Cardiac: Page 4
-
Courtesy of Boston Scientific
Boston Scientific, Edwards and Dexcom usher in second week of earnings
Johnson & Johnson, Abbott and Intuitive Surgical made a mixed start to earnings season last week.
By Nick Paul Taylor • Oct. 22, 2024 -
Courtesy of Boston Scientific
Boston Scientific wins FDA approval for Farapulse cardiac mapping
Stifel analyst Rick Wise said Boston Scientific can now offer “one-stop-shopping” with a pulsed field ablation catheter and integrated mapping system to treat atrial fibrillation.
By Susan Kelly • Oct. 21, 2024 -
Courtesy of Boston Scientific
Boston Scientific blood-blocking agent tied to additional 2 deaths, 8 injuries
After a February recall, Boston Scientific has warned physicians about new safety risks for Obsidio Embolic, which is now connected to a total of 15 injuries and four deaths.
By Nick Paul Taylor • Oct. 21, 2024 -
Courtesy of Johnson & Johnson
J&J’s recent medtech buys help to prop up devices unit
Johnson & Johnson’s medtech acquisitions over the past year have fueled growth for its cardiovascular group, offsetting challenges in businesses like orthopedics and surgery.
By Ricky Zipp • Oct. 15, 2024 -
Courtesy of Medtronic
Medtronic to evaluate Affera in ventricular tachycardia
The FDA approved an early feasibility study of Medtronic’s Affera mapping and ablation system and Sphere-9 catheter in patients with ventricular tachycardia, an abnormal heart rhythm.
By Susan Kelly • Oct. 15, 2024 -
Mario Tama via Getty Images
J&J, Abbott and Intuitive kick off latest medtech earnings season
From pulsed field ablation to diabetes tech and surgical robots, the updates will provide an early look at how key medtech markets performed last quarter.
By Nick Paul Taylor • Oct. 14, 2024 -
Courtesy of Abbott
Abbott enrolls pivotal PFA study 4 months ahead of schedule
The company reported the enrollment milestone alongside news that it received clearance to sell its Advisor HD Grid X Mapping Catheter and started a trial of its Tactiflex Duo Ablation Catheter.
By Nick Paul Taylor • Oct. 11, 2024 -
FG Trade via Getty Images
Elucid wins FDA 510(k) nod for heart plaque image analysis software
The software turns coronary CT angiography images into 3D models that quantify and classify plaque morphology to improve predictions of heart attack and stroke risk.
By Nick Paul Taylor • Oct. 4, 2024 -
Jolygon via Getty Images
FDA authorizes Pi-Cardia’s valve-in-valve TAVR device
Pi-Cardia designed the Shortcut device to mitigate the risk of coronary artery obstruction by splitting aortic valve leaflets before valve placement.
By Nick Paul Taylor • Oct. 3, 2024 -
halbergman via Getty Images
Top medtech conferences in 2025
The lineup includes industrywide conferences and events covering the latest medtech trends in diabetes, orthopedics, cardiac care and surgical robotics.
By Ricky Zipp • Updated Jan. 23, 2025 -
magicmine via Getty Images
Recalled heart devices had limited clinical testing, study finds
Just 30 of 157 heart devices with Class I recalls underwent premarket clinical testing, according to a study published in the Annals of Internal Medicine.
By Elise Reuter • Sept. 24, 2024 -
Courtesy of Cook Medical
Merit Medical inks $210M takeover of Cook’s lead management business
Merit predicts the portfolio, which includes devices used in procedures to remove or replace heart rhythm device leads, will add $40 million a year to its sales.
By Nick Paul Taylor • Sept. 18, 2024 -
Courtesy of Spectrawave
J&J leads $50M financing for imaging company Spectrawave
The Series B round will support commercial expansion and product additions for Spectrawave’s system used in the treatment of coronary artery disease.
By Susan Kelly • Sept. 11, 2024 -
SDI Productions via Getty Images
European heart group recommends renal denervation for some patients
The European Society of Cardiology said the treatment may be considered for certain patients with uncontrolled, drug-resistant high blood pressure but outlined lingering concerns.
By Nick Paul Taylor • Sept. 4, 2024 -
Permission granted by Johnson & Johnson
J&J to buy heart failure implant maker V-Wave for up to $1.7B
J&J has agreed to pay $600 million upfront for the private company as it works to expand its portfolio of cardiovascular devices.
By Susan Kelly • Aug. 20, 2024 -
Courtesy of Edwards Lifesciences
Edwards spends $1.2B on 2 heart device firms, extending deal streak
Alongside the acquisitions, Edwards reported a slowdown in its core TAVR business in the second quarter that sent its shares tumbling.
By Susan Kelly • July 25, 2024 -
Courtesy of Boston Scientific
Boston Scientific tips strong growth for Farapulse after successful launch
Questions on Boston Scientific’s pulsed field ablation system once again dominated the company’s earnings call.
By Ricky Zipp • July 24, 2024 -
Permission granted by Medtronic
Q&A‘Our next frontier is prediction’: Medtronic on AI and heart disease
Stacey Churchwell, who leads the company’s cardiovascular diagnostics and services business, says artificial intelligence is reducing false positives in its insertable cardiac monitors, saving clinicians valuable time.
By Susan Kelly • July 22, 2024 -
Permission granted by Abbott
Abbott previews PFA, over-the-counter CGM markets
Electrophysiology sales held up against rivals’ launches of pulsed field ablation systems. Meanwhile, Abbott is gauging sales of its first OTC CGMs.
By Elise Reuter • July 18, 2024 -
Courtesy of Edwards Lifesciences
Edwards to acquire Innovalve, stake in Affluent Medical
The heart valve specialist said in a federal filing that it expects to pay $300 million in cash for Innovalve Bio Medical when the deal closes.
By Susan Kelly • July 15, 2024 -
Permission granted by Boston Scientific
PFA devices are changing AFib treatment. The next wave could grow the market further.
New pulsed field ablation systems from Boston Scientific and Medtronic are already reshaping the cardiac ablation market, but upcoming devices could spur even greater adoption.
By Susan Kelly • June 17, 2024 -
Kardium raises $104M to develop pulsed field ablation system
Kardium will use the funding to complete a clinical study for pursuing regulatory approvals and build its manufacturing, clinical support and commercial teams.
By Susan Kelly • June 12, 2024 -
Sarah Silbiger via Getty Images
Abbott issues recall for Heartmate system monitor
Abbott’s heart pump system and related products have been part of multiple Class I recalls this year.
By Susan Kelly • June 11, 2024 -
Courtesy of Edwards Lifesciences
Sapien valve performs equally well for small and large aortic annuli, Edwards finds
The analysis adds to a debate about the effectiveness of Edwards versus Medtronic TAVR devices in patients with small aortic annuli, a fibrous ring around the heart’s valve.
By Nick Paul Taylor • June 6, 2024 -
Courtesy of Medtronic
Medtronic touts demand for PFA, adding to hype for the new ablation tech
CEO Geoff Martha told investors there has already been “strong adoption” of PFA devices and the category will be a big part of Medtronic's revenue growth in fiscal year 2025.
By Ricky Zipp • May 23, 2024
Previous
